We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is reviewing Pfizer’s Biologics License Application for 20vPnC under a Priority Review designation and the agency’s decision is anticipated in June. Read More
Takeda Pharmaceutical’s dengue vaccine candidate, TAK-003, offered strong continued protection against dengue fever, especially infection requiring hospitalization, for up to three years with no significant safety risks, according to a late-stage study. Read More
Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. Read More
The UK’s National Institute for Health and Care Excellence (NICE) has rejected Bristol Myers Squibb’s multiple sclerosis (MS) drug Zeposia (ozanimod) for use by the National Health Service over cost concerns. Read More
Biogen’s experimental gene therapy, cotoretigene toliparvovec, failed to show efficacy in a phase 2/3 study of patients suffering from a rare, inherited retinal disease. Read More
A UK study has shown that individuals over 80 years old had significantly higher antibody responses when given their second Pfizer/BioNTech vaccine dose after 12 weeks as opposed to the standard three-week interval. Read More